Global Cancer Monoclonal Antibodies Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 210 pages | ID: G866321E82AEN
Precision Business Insights (PBI)

Abstracts

Global Cancer Monoclonal Antibodies Market:

Global cancer monoclonal antibodies market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for cancer monoclonal antibodies is projected to reach US$ XX Mn by 2023.

A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of cancer cell when antibody binds to antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have least adverse effects than other cancer treating drugs.

The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue of cancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market. Monoclonal antibodies are very specific in nature and have limited targets.

Cancer monoclonal antibodies market has been segmented based on application, type and conjugation, and distribution channel

Base on application, cancer monoclonal antibodies market is segmented into

• Breast Cancer
• Blood Cancer
• Liver Cancer
• Brain cancer
• Colorectal Cancer
• Others

Based on type of antibody, cancer monoclonal antibodies market is segmented into

• Murine Antibodies
• Humanized Antibodies
• Chimeric Antibodies

Based on conjugation, cancer monoclonal antibodies market is segmented into

• Immunocytokines
• Immunoliposome
• Radioimmunotherapy
• Antibody Directed Enzyme Prodrug Therapy(ADEPT)

Based on distribution channel, cancer monoclonal antibodies market segmented into

• Hospital Pharmacies
• Retail Pharmacies
• Clinics

Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.

Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.

Some of the players in cancer monoclonal antibodies market are Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi (France) and AstraZeneca (U.K.) to name a few.

In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca’s durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma

In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology’s tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET INTRODUCTION

2.1. Global Cancer Monoclonal Antibodies Market– Taxonomy
2.2. Global Cancer Monoclonal Antibodies Market–Definitions
  2.2.1. Application
  2.2.2. Distribution Channel

3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cancer Monoclonal Antibodies Market Dynamics – Factors Impact Analysis
3.6. Global Cancer Monoclonal Antibodies Market– Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Cancer Monoclonal Antibodies Market– Recent Product Launches

4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Breast Cancer
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Blood Cancer
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Liver Cancer
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Brain cancer
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Colorectal Cancer
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Others
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis

6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY TYPE OF ANTIBODY, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Murine Antibodies
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Humanized Antibodies
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Chimeric Antibodies
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY CONJUGATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Immunocytokines
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Immunoliposome
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Radioimmunotherapy
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis

8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospital Pharmacies
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis

9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Breast Cancer
    10.1.1.2. Blood Cancer
    10.1.1.3. Liver Cancer
    10.1.1.4. Brain cancer
    10.1.1.5. Colorectal Cancer
    10.1.1.6. Others
  10.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Murine Antibodies
    10.1.2.2. Humanized Antibodies
    10.1.2.3. Chimeric Antibodies
  10.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Immunocytokines
    10.1.3.2. Immunoliposome
    10.1.3.3. Radioimmunotherapy
    10.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
  10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Hospital Pharmacies
    10.1.4.2. Retail Pharmacies
    10.1.4.3. Online Pharmacies
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
  10.1.6. North America Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
  10.1.7. North America Cancer Monoclonal Antibodies Market Dynamics – Trends

11. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Breast Cancer
    11.1.1.2. Blood Cancer
    11.1.1.3. Liver Cancer
    11.1.1.4. Brain cancer
    11.1.1.5. Colorectal Cancer
    11.1.1.6. Others
  11.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Murine Antibodies
    11.1.2.2. Humanized Antibodies
    11.1.2.3. Chimeric Antibodies
  11.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Immunocytokines
    11.1.3.2. Immunoliposome
    11.1.3.3. Radioimmunotherapy
    11.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
  11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Hospital Pharmacies
    11.1.4.2. Retail Pharmacies
    11.1.4.3. Online Pharmacies
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.5.1. Germany
    11.1.5.2. UK
    11.1.5.3. France
    11.1.5.4. Spain
    11.1.5.5. Italy
    11.1.5.6. Russia
    11.1.5.7. Poland
    11.1.5.8. Rest of Europe
  11.1.6. Europe Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
  11.1.7. Europe Cancer Monoclonal Antibodies Market Dynamics – Trends

12. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Breast Cancer
    12.1.1.2. Blood Cancer
    12.1.1.3. Liver Cancer
    12.1.1.4. Brain cancer
    12.1.1.5. Colorectal Cancer
    12.1.1.6. Others
  12.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Murine Antibodies
    12.1.2.2. Humanized Antibodies
    12.1.2.3. Chimeric Antibodies
  12.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Immunocytokines
    12.1.3.2. Immunoliposome
    12.1.3.3. Radioimmunotherapy
    12.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
  12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Hospital Pharmacies
    12.1.4.2. Retail Pharmacies
    12.1.4.3. Online Pharmacies
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    12.1.5.1. Japan
    12.1.5.2. China
    12.1.5.3. India
    12.1.5.4. ASEAN
    12.1.5.5. Australia & New Zealand
    12.1.5.6. Rest of Asia-Pacific
  12.1.6. Asia-Pacific Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
  12.1.7. Asia-Pacific Cancer Monoclonal Antibodies Market Dynamics – Trends

13. LATIN AMERICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Breast Cancer
    13.1.1.2. Blood Cancer
    13.1.1.3. Liver Cancer
    13.1.1.4. Brain cancer
    13.1.1.5. Colorectal Cancer
    13.1.1.6. Others
  13.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Murine Antibodies
    13.1.2.2. Humanized Antibodies
    13.1.2.3. Chimeric Antibodies
  13.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Immunocytokines
    13.1.3.2. Immunoliposome
    13.1.3.3. Radioimmunotherapy
    13.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
  13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Hospital Pharmacies
    13.1.4.2. Retail Pharmacies
    13.1.4.3. Online Pharmacies
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.5.1. Brazil
    13.1.5.2. Mexico
    13.1.5.3. Argentina
    13.1.5.4. Venezuela
    13.1.5.5. Rest of Latin America
  13.1.6. Latin America Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
  13.1.7. Latin America Cancer Monoclonal Antibodies Market Dynamics – Trends

14. MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  14.1.1. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.1.1. Breast Cancer
    14.1.1.2. Blood Cancer
    14.1.1.3. Liver Cancer
    14.1.1.4. Brain cancer
    14.1.1.5. Colorectal Cancer
    14.1.1.6. Others
  14.1.2. Antibody Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.2.1. Murine Antibodies
    14.1.2.2. Humanized Antibodies
    14.1.2.3. Chimeric Antibodies
  14.1.3. Conjugation Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.3.1. Immunocytokines
    14.1.3.2. Immunoliposome
    14.1.3.3. Radioimmunotherapy
    14.1.3.4. Antibody Directed Enzyme Prodrug Therapy(ADEPT)
  14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.4.1. Hospital Pharmacies
    14.1.4.2. Retail Pharmacies
    14.1.4.3. Online Pharmacies
  14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.5.1. Gulf Cooperation Council (GCC) Countries
    14.1.5.2. Israel
    14.1.5.3. South Africa
    14.1.5.4. Rest of MEA
  14.1.6. MEA Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2017 – 2023
  14.1.7. MEA Cancer Monoclonal Antibodies Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Merck & Co. Inc. (U.S.)
  15.2.2. F. Hoffmann-La Roche AG (Switzerland)
  15.2.3. Spectrum Pharmaceuticals (U.S.)
  15.2.4. Eli Lilly and Company (U.S.)
  15.2.5. Amgen Inc. (U.S.)
  15.2.6. Bristol-Meyer Squibb (U.S.)
  15.2.7. Sanofi (France)
  15.2.8. AstraZeneca (U.K.)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS